SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Regeneron Pharmaceuticals, Inc. Release: EYLEA® (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Your Message